振动控制瞬时弹性成像与磁共振弹性成像在代谢功能障碍相关脂肪性肝病患者肝纤维化分期中的一致性
该回顾性研究纳入103例疑似代谢功能障碍相关脂肪性肝病患者,评估振动控制瞬时弹性成像与磁共振弹性成像在肝纤维化分期及判断resmetirom治疗资格方面的一致性。结果显示两种方法一致性为一般至中等,振动控制瞬时弹性成像倾向于高估纤维化分期,其受控衰减参数仅对重度脂肪变检测可靠。
要点
- 振动控制瞬时弹性成像较磁共振弹性成像倾向于高估肝纤维化分期,42例(40.7%)被分配到更高分期。
- 振动控制瞬时弹性成像判断F2-F3期33例 vs 磁共振弹性成像18例,一致性Cohen Kappa为0.215。
- 振动控制瞬时弹性成像受控衰减参数诊断轻、中、重度脂肪变的AUC分别为0.547、0.754、0.813。
核心结论
- 振动控制瞬时弹性成像与磁共振弹性成像在肝纤维化分期上一致性为一般至中等,振动控制瞬时弹性成像倾向于分配更高纤维化分期,其受控衰减参数仅能可靠检测重度脂肪变。
研究设计与样本
- 回顾性研究纳入103例疑似代谢功能障碍相关脂肪性肝病患者(61例男性,平均年龄54.7岁),均接受振动控制瞬时弹性成像和MRI/磁共振弹性成像检查。
诊断标准与关键数值
- 振动控制瞬时弹性成像与磁共振弹性成像在各纤维化分期组合(F0-F1 vs F2-F4、F0-F2 vs F3-F4、F0-F3 vs F4)的分布差异均有统计学意义(均p < 0.001),Cohen Kappa值为0.305-0.554;判断F2-F3期(符合resmetirom治疗资格)的Cohen Kappa为0.215;振动控制瞬时弹性成像受控衰减参数诊断轻度、中度、重度脂肪变的AUC分别为0.547、0.754、0.813(以MRI-PDFF为参考标准)。
临床应用与阅片要点
- 磁共振弹性成像可能成为为代谢功能障碍相关脂肪性肝炎患者选择resmetirom治疗的优选模态,因其与振动控制瞬时弹性成像相比可能节省大量成本(原文估计每年节省707,701美元)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the concordance between vibration-controlled transient elastography (VCTE) and magnetic resonance elastography (MRE) for staging liver fibrosis and assessing hypothetical eligibility for resmetirom treatment in a cohort of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). A secondary objective was to assess the performance of VCTE for liver fat quantification.
MATERIALS AND METHODS: This retrospective study included 103 patients (61 males; mean age 54.7 years) with suspected MASLD who underwent VCTE and MRI/MRE. The following parameters were extracted: liver stiffness (LS) from both techniques, controlled attenuation parameter (CAP) from VCTE, and MRI-proton density fat fraction (PDFF). Agreement and fibrosis stage distributions were assessed using Cohen's Kappa and McNemar's tests. ROC analysis assessed the performance of CAP against MRI-PDFF (considered the reference for steatosis).
RESULTS: A significant difference was observed in assigned fibrosis stage distributions between VCTE and MRE across all combinations (F0-F1 vs F2-F4, F0-F2 vs F3-F4, F0-F3 vs F4, all p < 0.001) with fair to moderate agreement between modalities (Cohen's Kappa values 0.305-0.554). VCTE assigned a higher fibrosis stage in 42 patients (40.7%). Thirty-three vs eighteen patients were classified as F2-F3 (qualified for resmetirom treatment) with VCTE vs MRE (Cohen's Kappa 0.215), which was associated with estimated cost savings of $707,701/year with MRE. VCTE-CAP achieved AUCs of 0.547, 0.754, and 0.813 for diagnosing mild, moderate, and severe steatosis, respectively.
CONCLUSION: VCTE and MRE have fair to moderate agreement for fibrosis staging, with VCTE tending to assign a higher fibrosis stage compared to MRE. VCTE-CAP reliably detects only severe steatosis.
KEY POINTS: Question What is the agreement between VCTE and MRE in staging fibrosis in MASLD and identifying patients with F2-F3 disease? Findings Limited concordance was found between VCTE and MRE for staging liver fibrosis and identifying F2-F3 disease; VCTE tended to assign higher fibrosis stages compared to MRE. Clinical relevance MRE could represent the modality of choice for selecting patients with metabolic dysfunction-associated steatohepatitis for resmetirom therapy as it potentially offers high cost-savings compared to VCTE.
引用
- Mathur A, Ozkaya E, Rosberger S, et al. Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease. Eur Radiol. 2025. PMID: 40159342. doi:10.1007/s00330-025-11533-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。